Bone Mineral Density News and Research

RSS

Interleukin Genetics and Amway Global sign partnership agreement

Interleukin Genetics, Inc. announced today it has entered into an agreement with Amway Global. With this agreement, Amway Global Independent Business Owners will be able to sell Interleukin Genetics' Inherent Health(TM) brand of genetic tests, including the new Weight Management Genetic Test.

29 Oct 2009

Steroid-induced osteoporosis can now be treated with Teriparatide

A recent study determined glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone. Researchers found patients with glucocorticoid-induced OP who were treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate.

29 Oct 2009

DaVita to demonstrate clinical outcomes, patient care and nutrition through 43 abstracts

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research®, today announced that company representatives will deliver 43 abstracts—40 posters and three oral presentations—at this year’s American Society of Nephrology’s (ASN) Renal Week to be held in San Diego, Calif., from Oct. 27 – Nov. 1, 2009.

24 Oct 2009

Interleukin Genetics to present new genetic findings on obesity and osteoporosis

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it will present new genetic findings in the fields of obesity and osteoporosis at medical meetings later this month.

13 Oct 2009

Gluten-free diet leads to complete recovery of bone mineralization in CD affected children

Celiac disease (CD) is an inherited intestinal disorder characterized by life-long intolerance to the ingestion of gluten, a protein found in wheat, rye, and barley. Although CD can be diagnosed at any age, it commonly occurs during early childhood (between 9 and 24 months). Reduced bone mineral density is often found in individuals with CD.

9 Oct 2009

$Hip fracture patients more likely to be evaluated for osteoporosis than wrist fracture patients$

Hip fracture patients more likely to be evaluated for osteoporosis than wrist fracture patients

A study published in the October 2009 issue of the Journal of Bone and Joint Surgery suggests a disconnect between the way wrist-fracture patients and those with a spine or hip fracture are managed and evaluated. The study, conducted in 2007 among 97 percent of the women in Korea, reviewed the incidence of fractures around the hip, spine, and wrist in female patients age 50 and older and the prescription frequencies of bone density scans for osteoporosis, along with the use of medications for its treatment.

3 Oct 2009

Results of IES presented at ECCO

Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the risk of disease-free survival (DFS) events. In addition, IES showed that AROMASIN prolonged overall survival (OS) in the ER+/unknown population with a 14% reduction in the risk of dying. These results demonstrate that the benefits of treatment are maintained in long term follow-up. These results were presented at the joint ECCO 15/ESMO 34 meeting in Berlin, Germany.

23 Sep 2009

Osteoporosis a growing concern in Asia

A new audit report issued by the International Osteoporosis Foundation (IOF) today shows that osteoporosis is a serious and growing problem throughout Asia.

22 Sep 2009

Study: Antiretroviral drugs may prevent HIV infection in women

Hopeful that some of the same antiretroviral (ARV) drugs used to treat HIV infection can also prevent it, researchers from the Microbicide Trials Network have enrolled the first participants into a new, large-scale clinical trial testing two approaches of the strategy in women.

17 Sep 2009

Positive results from Merck's Phase IIB clinical study of odanacatib for treating osteoporosis

New data from a Phase IIB clinical study of odanacatib, Merck & Co., Inc.'s oral, once-weekly investigational treatment for osteoporosis, showed that when stopping treatment after two years, the increases in lower back (lumbar spine) bone mineral density (BMD) were reversed over the next year, while BMD at the hip (femoral neck) remained above levels observed at the start of the study.

15 Sep 2009

Muscular thighs protect women from developing symptomatic knee osteoarthritis

new study by researchers at the University of Iowa Hospitals and Clinics found that thigh muscle strength does not predict the occurrence of knee osteoarthritis (OA) uncovered in x-rays, but does predict incidence of painful or stiff knee OA. Women with the strongest quadriceps muscles appeared to be protected against the development of knee OA symptoms. Details of this study appear in the September issue of Arthritis Care & Research.

27 Aug 2009

$Denosumab reduces fractures in postmenopausal women with osteoporosis$

Denosumab reduces fractures in postmenopausal women with osteoporosis

Fractures are a major cause of disability and health care costs among postmenopausal women. Now a study in the New England Journal of Medicine highlights an alternative therapy that prevents fractures in postmenopausal women with osteoporosis.

18 Aug 2009

Metabolic bone disease in cirrhosis patients

Long-standing liver disease has long been recognized to result in fragile bones with increased risk of fractures. In various international studies, the overall incidence has varied from 11% to 48%, with a fracture rate of 3%-44%.

10 Aug 2009

Stroke doubles patients' risk of breaking a hip or femur

Stroke survivors have about twice the risk of breaking a hip or femur compared to those without stroke - and the risk is even greater for younger patients, women and those with recent strokes, Dutch researchers report in Stroke: Journal of the American Heart Association.

6 Aug 2009

Zoledronic acid may save lives by strengthening immune system

An osteoporosis drug proven to save lives after hip fractures may do so by strengthening the body's immune system, according to geriatrics researchers at Duke University Medical Center.

19 Jul 2009

Improved bone healing with osteoporosis drug teriparatide

Bone fractures might heal faster if the patient is injected with medications. This is the outcome of a unique study of 102 women with wrist fractures.

16 Jul 2009

Happier, healthier, more productive hens on omega-3?

Most of us are aware of the potential health benefits of omega-3 found in fish oil and flax seed. Now researchers are looking at how omega-3 may help laying hens avoid bone damage.

13 Jul 2009

Vegetarian diet leads to lower bone density

Even though there has been for some time concern on the part of experts that a vegetarian diet may have negative impact on bone health, until now that opinion has largely been based on anecdotal evidence and a range of contradictory findings which have often relied on studies which experts say are too small to be biologically relevant.

5 Jul 2009

Discovery of a genetic link to risk of kidney stones and osteoporosis

A discovery by scientists at deCODE genetics and academic colleagues from Iceland, the Netherlands and Denmark has pointed to a common biological mechanism contributing to both kidney stones and decreased bone mineral density (BMD).

30 Jun 2009

Delay in diagnosis of menopause-like condition in young women linked to low bone density

Women and young girls who experience delays in diagnosing a premature, menopause-like condition face increased risk of low bone density, according to new research by scientists at the National Institutes of Health. A delay in diagnosing the condition, called primary ovarian insufficiency, may make women more susceptible to osteoporosis and fractures later in life, the researchers concluded.

21 Jun 2009